Anidulafungin
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Anidulafungin
Anidulafungin: Known uses and market status in Canada
Summary
The TxGNN deep-learning model has no candidate indication with a score of 0.99 or higher for Anidulafungin, so there is currently no new predicted indication. The drug’s own recorded uses are listed below. They come from a license in another country, not from model predictions.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 3 |
| Evidence level | Not applicable |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| candidiasis | licence in another country |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| candidemia |
| esophageal candidiasis |
Canada Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 02330695 | ERAXIS | Valid |
Safety Considerations
- Knowledge-graph contraindication signals: liver disease and gallbladder disease. These come from drug-disease relationships in the knowledge graph, not from product label text, and should be checked against the package insert.
- Drug Interactions: one minor interaction was identified, with cyclosporine.
Please refer to the package insert for full warnings and contraindications.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.